We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

FTC Requires Two "Gold-Standard" Studies in Sketchers Consent Decree

18 May 2012
For the second time in eight months, the Federal Trade Commission (FTC) has obtained a multi-million dollar settlement as the price paid for alleged deceptive advertising of footwear promoted to help customers lose weight and strengthen muscles. The FTC announced its $40 million settlement with Sketchers earlier this week. According to the FTC, Sketchers incorrectly reported the results of clinical studies on weight loss achieved with its Shape-ups shoes.
FTC Requires Two "Gold-Standard" Studies in Sketchers Consent Decree

Notably, the consent decree entered into by Sketchers requires the company to have at least two well-controlled human clinical studies to substantiate weight loss claims. The Sketchers case is the most recent example of FTC’s pattern of implementing the potentially more stringent requirement of two placebo-controlled, double-blind clinical studies as substantiation for health-related claims (the so-called gold standard), rather than the traditional standard of “competent and reliable evidence.” Interestingly, FTC’s order in the Reebok case only required one gold-standard study. Although FTC has stated that it is not requiring two clinical studies as a blanket substantiation standard, the Sketchers case provides another example of the types of claims FTC views as requiring a more precise level of support.

Veronica Knapp

Loading data